Dana–Farber Cancer Institute
Dana–Farber Cancer Institute is a hospital in Massachusetts, United States. It was founded in 1947. Its headquarters are in Boston.
- Founded
- 1947
- Headquarters
- Boston
- Industry
- hospitals and rehabilitation
- Country
- United States
All 12 facts, and where they come from
Facts
12 facts · 0 confirmed by two sources · 3 cited · 9 from one source
Where this comes from
Papalocal keeps its own record. It started from these sources; what each one said is kept here as it was copied, so a change on their side never changes this page by itself. Tap one to read its version.
What Wikidata says · copied November 16, 2026 · revision 2568350915
- Described as
- hospital in Massachusetts, United States
- Other names
- Dana-Farber Cancer Institute
- What it is
- hospital; research institute; NCI-designated Cancer Center
- Founded
- 1947 · 1 reference
- Headquarters
- Boston · 1 reference
- Located in
- Massachusetts
- Country
- United States · 1 reference
- Industry
- hospitals and rehabilitation; research
- Named after
- Sidney Farber · 2 references; Dana Foundation · 1 reference
- Official website
- http://www.dana-farber.org/ · 1 reference
- Wikipedias with a page
- 9
Wikidata item Q1159198 (wikidata.org/wiki/Q1159198), public domain (CC0). Copied 2026-11-16.
What Wikipedia says · copied November 16, 2026 · revision 1385268630
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts. Dana–Farber is the founding member of the Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and is a principal teaching affiliate and research institute of Harvard Medical School.
As of 2024, Dana–Farber is ranked as the sixth-best cancer hospital in the US. Two Nobel laureates in Physiology or Medicine are among its past and present faculty.
In 2024, an investigation revealed evidence of research misconduct in dozens of studies authored by Dana–Farber researchers, including then-president and chief executive officer Laurie Glimcher, the executive vice president and chief operating officer, and the research integrity officer. In response to these findings, Dana–Farber retracted seven papers and corrected 31 others. In October 2024, Laurie Glimcher stepped down as president and CEO. In December 2025, Dana Farber agreed to pay $15 million to settle the fraud allegations, including over $2.5 million to scientist Sholto David.
From the Wikipedia article “Dana–Farber Cancer Institute” (en.wikipedia.org/wiki/Dana–Farber_Cancer_Institute), by its contributors, under CC BY-SA 4.0 (creativecommons.org/licenses/by-sa/4.0/). Copied 2026-11-16; not changed.
Confirmed Two sources agree. Cited One source, and it names where it got it. One source One source, without a reference of its own. Sources disagree The sources disagree. We show the best-supported value and keep theirs below.
